RedHill Biopharma Ltd. announced the U.S. Food and Drug Administration's (FDA) approval of its supplemental new drug application (sNDA) for Talicia, allowing a change to a more flexible three times daily (TID), taken at least 4 hours apart with food, dosing regimen for H. pylori eradication. This differs from the previously approved dosing regimen (Q8H), which required dosing every eight hours with food, by enabling patients to follow a convenient "breakfast, lunch and dinner" dosing routine, which may support increased patient adherence and optimize the potential for successful H. pylori eradication.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.424 USD | -1.83% | -3.53% | -70.43% |
06-06 | RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board | CI |
05-06 | Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib | MT |
1st Jan change | Capi. | |
---|---|---|
-70.43% | 13.76M | |
+0.82% | 91.94B | |
-3.16% | 38.74B | |
+64.83% | 26.66B | |
-12.60% | 15.32B | |
-5.89% | 13.3B | |
-11.38% | 11.65B | |
+156.85% | 10.37B | |
-49.84% | 10.12B | |
+2.32% | 9.06B |
- Stock Market
- Equities
- RDHL Stock
- News RedHill Biopharma Ltd.
- Redhill Biopharma Ltd. Announces Fda Snda Approval for Talicia®?